Extended indication Extension of indication to include treatment of severe chronic anemia (haemoglobin level < 6 g/dL or < 7 g/dL with poor clinical or functional t
Therapeutic value No judgement
Registration phase Registration application pending

Product

Active substance Hydroxycarbamide
Domain Cardiovascular diseases
Reason of inclusion Indication extension IND
Main indication Other non-oncological hematological medications
Extended indication Extension of indication to include treatment of severe chronic anemia (haemoglobin level < 6 g/dL or < 7 g/dL with poor clinical or functional tolerance) in adults, adolescents and children older than 2 years suffering from sickle cell syndrome.
Proprietary name Siklos
Manufacturer Nordic Pharma
Mechanism of action Unknown
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP Unknown
Submission date July 2020
Expected Registration May 2021
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No judgement

This assessment does not indicate any potential inclusion in the package.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Additional remarks Gemiddelde prijs per 30 stuks SIKLOS, TABLET 1000MG € 555,78.

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information